User login
Vigorous physical activity may help lower the risk of non-Hodgkin’s lymphoma, Terry Boyle, Ph.D., and his coauthors reported in Cancer Epidemiology, Biomarkers & Prevention.
In a case-control study of 820 non-Hodgkin’s lymphoma (NHL) patients and 848 controls, those in the higher (second, third, and fourth) quartiles of lifetime vigorous intensity exercise had a 25%-30% lower risk of NHL than did those in the lower quartile (odds ratios of 0.69; 0.68; and 0.75, respectively).
“Given this finding, more research on physical activity intensity and timing in relation to NHL risk is warranted,” Dr. Boyle and his associates wrote.
Read the full article here: Cancer Epidemiol. Biomarkers Prev. 2015;24:873-7 (doi:10.1158/1055-9965.EPI-14-1303).
Vigorous physical activity may help lower the risk of non-Hodgkin’s lymphoma, Terry Boyle, Ph.D., and his coauthors reported in Cancer Epidemiology, Biomarkers & Prevention.
In a case-control study of 820 non-Hodgkin’s lymphoma (NHL) patients and 848 controls, those in the higher (second, third, and fourth) quartiles of lifetime vigorous intensity exercise had a 25%-30% lower risk of NHL than did those in the lower quartile (odds ratios of 0.69; 0.68; and 0.75, respectively).
“Given this finding, more research on physical activity intensity and timing in relation to NHL risk is warranted,” Dr. Boyle and his associates wrote.
Read the full article here: Cancer Epidemiol. Biomarkers Prev. 2015;24:873-7 (doi:10.1158/1055-9965.EPI-14-1303).
Vigorous physical activity may help lower the risk of non-Hodgkin’s lymphoma, Terry Boyle, Ph.D., and his coauthors reported in Cancer Epidemiology, Biomarkers & Prevention.
In a case-control study of 820 non-Hodgkin’s lymphoma (NHL) patients and 848 controls, those in the higher (second, third, and fourth) quartiles of lifetime vigorous intensity exercise had a 25%-30% lower risk of NHL than did those in the lower quartile (odds ratios of 0.69; 0.68; and 0.75, respectively).
“Given this finding, more research on physical activity intensity and timing in relation to NHL risk is warranted,” Dr. Boyle and his associates wrote.
Read the full article here: Cancer Epidemiol. Biomarkers Prev. 2015;24:873-7 (doi:10.1158/1055-9965.EPI-14-1303).